To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment
Objective: The choice of neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC) is controversial.